Matthew Wisnieff is a senior litigation associate in the New York office and a member of the Firm's Intellectual Property global practice. Matthew represents domestic and foreign clients in complex commercial litigation, focusing on intellectual property disputes as well as matters concerning the intersection of patent and antitrust law. He regularly represents industry leaders in the pharmaceutical, medical device, and technology industries, such as Allergan/AbbVie, Pfizer, Boehringer Ingelheim, and Abiomed, at both the trial and appellate levels.
Matthew's practice covers a wide range of matters, including patent, trademark, trade secret, and copyright disputes, litigation under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act, class action litigation, IP licensing disputes, and advising clients on patent and antitrust law. In addition to high-stakes IP matters, Matthew has extensive experience litigating the IP aspects of pharmaceutical-antitrust cases and standard-essential patent (SEP)/FRAND disputes. Recently, Matthew successfully represented CosmoKey in a significant decision before the Court of Appeals for the Federal Circuit, winning a rare reversal under the Alice doctrine. In the past, he has also participated in litigation through trial of federal bankruptcy proceedings arising out of the 2008 financial crisis.
Matthew also has extensive experience representing pro bono clients in the area of environmental law. He regularly litigates and advises on Clean Water Act enforcement disputes on behalf of an environmental nonprofit organization. In the past, Matthew has provided legal advice assisting parents of New York City public school students in prevailing in an environmental dispute under the Resource Conservation and Recovery Act.
Representing CosmoKey in its appeal of a finding of unpatentability under Section 101 before the Court of Appeals for the Federal Circuit – winning reversal under the Alice doctrine.
Representation of Allergan/AbbVie in multiple antitrust class actions concerning the settlement of Hatch-Waxman patent litigation between brand and generic pharmaceutical companies.
Represented Abiomed in multiple patent disputes in the medical device industry.
Represented leading global pharmaceutical company in litigation under the Biologics Price Competition and Innovation Act.
Represented Boehringer Ingelheim in antitrust class action/multi-district litigation concerning the settlement of Hatch-Waxman patent litigation between brand and generic pharmaceutical companies.
Represented Pfizer in Hatch-Waxman patent litigation against group of 11 generic drug manufacturers.
Represented Pfizer in multiple antitrust class action matters concerning Hatch-Waxman patent litigation settlements between brand and generic pharmaceutical companies.
Best Lawyers: Ones to Watch in America in Patent Law, 2023
Pro Bono Award for Outstanding Legal Service, 2019
Pro Bono Award for Outstanding Legal Service, 2016
Pro Bono Award for Outstanding Legal Service, 2013
Pro Bono Award for Outstanding Legal Service, 2012